concurrent track: disease modeling and drug discovery
Examining advances in in vivo, in vitro, and in silico disease models to enable drug screening, toxicity assessment, and therapeutic development.
Organized by:
Shuibing Chen, PhD, Weill Cornell Medical College, USA
Hongkui Deng, PhD, Peking University, China
*Additional invited and abstract-selected speakers to be determined. Session descriptions and titles may change slightly.
aging models and age-related diseases
Li Gan, PhD, Weill Cornell Medical College, USA
Weiqi Zhang, PhD, China National Center for Bioinformation and Beijing Institute of Genomics, Chinese Academy of Sciences, China
-
This session explores the biological mechanisms of aging and highlights opportunities for intervention in age-related diseases such as Alzheimer’s and metabolic disorders.
precision medicine and drug evaluation
Daniela Cornacchia, PhD, AstraZeneca, Sweden
Hongjun Song, PhD, University of Pennsylvania, USA
-
This session focuses on the application of stem cell-based models in drug development and precision medicine, including toxicity testing.
advanced organoid models
Sasha Mendjan, PhD, Institute of Molecular Biotechnology, IMBA, Austria
Samira Musah, PhD, Duke University, USA
-
This session features organoid models that incorporate vascular, immune, and microtissue components to improve physiological relevance in disease modeling.
new approach methodologies
Sonja Beken, PhD, Federal Agency for Medicines and Health Products, Belgium
Jinmiao Chen, PhD, Duke-NUS Medical School, Singapore
-
This session showcases New Approach Methodologies (NAMs) including in vitro and in silico techniques that advance research and accelerate translation. It also features a regulatory perspective on the role of NAMs’ in drug development and safety assessment.